Orer, H. S. Et Al. 2022. Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC). Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (ELECTR NETWORK).

Orer, H. S., Nomak, G., Oksuzoglu, B., Senturk, R., ERALP, Y., Yumuk, F., ... Nomak, H.(2022). Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC) . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK

Orer, H. Et Al. "Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022

Orer, H. S. Et Al. "Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK, 2022

Orer, H. S. Et Al. (2022) . "Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={H. S. Orer Et Al. }, title={Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={}, country={ELECTR NETWORK}, year={2022}}